APA (7th ed.) Citation

S, M., IP, K., H, C., F, W., S, K., SW, T., . . . S, P. (2023). Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma. Experimental hematology & oncology, 12(1), 78. https://doi.org/10.1186/s40164-023-00443-w

Chicago Style (17th ed.) Citation

S, Mittal, et al. "Preclinical Activity of Selinexor in Combination with Eribulin in Uterine Leiomyosarcoma." Experimental Hematology & Oncology 12, no. 1 (2023): 78. https://doi.org/10.1186/s40164-023-00443-w.

MLA (9th ed.) Citation

S, Mittal, et al. "Preclinical Activity of Selinexor in Combination with Eribulin in Uterine Leiomyosarcoma." Experimental Hematology & Oncology, vol. 12, no. 1, 2023, p. 78, https://doi.org/10.1186/s40164-023-00443-w.